Yu-Chun Hsu
Overview
Explore the profile of Yu-Chun Hsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
318
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Z, Lin C, Hsu Y, Chen J, Chang P, Wen M, et al.
Int J Med Inform
. 2024 Dec;
195:105742.
PMID: 39631267
Background: The 12-lead electrocardiogram (ECG) is an established modality for cardiovascular assessment. While deep learning algorithms have shown promising results for analyzing ECG data, the limited availability of labeled datasets...
2.
Hsu Y, Lin P, Teng W, Hsieh Y, Chen W, Su C, et al.
Cancers (Basel)
. 2024 Oct;
16(20).
PMID: 39456553
Background: The combination of anti-angiogenic therapy and immune checkpoint inhibitors has revolutionized the management of unresectable hepatocellular carcinoma (uHCC). While an early-phase study demonstrated promising outcomes for lenvatinib plus pembrolizumab...
3.
Chen T, Hsiao S, Chen Y, Yen H, Su W, Hsu Y, et al.
Sci Rep
. 2024 Apr;
14(1):9068.
PMID: 38643245
Due to the comprehensive hepatitis B virus vaccination program in Taiwan since 1986, the development of antiviral therapy for chronic hepatitis B and chronic hepatitis C infection and covered by...
4.
Ma X, Shyer M, Harris K, Wang D, Hsu Y, Farrell C, et al.
PLOS Digit Health
. 2024 Apr;
3(4):e0000479.
PMID: 38598464
The rate of progression of Alzheimer's disease (AD) differs dramatically between patients. Identifying the most is critical because when their numbers differ between treated and control groups, it distorts the...
5.
Lin P, Hsu Y, Kao Y, Teng W, Hsieh Y, Chen W, et al.
Am J Cancer Res
. 2024 Apr;
14(3):1306-1315.
PMID: 38590407
For advanced hepatocellular carcinoma (HCC), the best second-line treatment after first-line treatment with sorafenib is unclear. This study aimed to compared the efficacy of second-line regorafenib (a tyrosine kinase inhibitor)...
6.
Dai Y, Hsu Y, Fernandes B, Zhang K, Li X, Enduru N, et al.
J Alzheimers Dis
. 2024 Feb;
97(4):1807-1827.
PMID: 38306043
Background: The progressive cognitive decline, an integral component of Alzheimer's disease (AD), unfolds in tandem with the natural aging process. Neuroimaging features have demonstrated the capacity to distinguish cognitive decline...
7.
Su C, Teng W, Lin P, Wu T, Hsu Y, Hsieh Y, et al.
Am J Cancer Res
. 2023 Dec;
13(11):5482-5492.
PMID: 38058809
Atezolizumab plus bevacizumab (A+B) is used to treat unresectable hepatocellular carcinoma (HCC), but the optimal rescue therapy after A+B remains unclear. Combining locoregional therapy (LRT) with systemic treatment has been...
8.
Chang P, Liu Z, Huang Y, Hsu Y, Chen J, Lin C, et al.
Front Cardiovasc Med
. 2023 Nov;
10:1245614.
PMID: 37965090
Background: The risk of mortality is relatively high among patients who visit the emergency department (ED), and stratifying patients at high risk can help improve medical care. This study aimed...
9.
Chu Y, Tang K, Hsu Y, Huang T, Wang D, Li W, et al.
BMC Med Inform Decis Mak
. 2023 Jul;
23(1):131.
PMID: 37480040
Background: Monitoring blood pressure and peripheral capillary oxygen saturation plays a crucial role in healthcare management for patients with chronic diseases, especially hypertension and vascular disease. However, current blood pressure...
10.
Wu W, Chang K, Hsu Y, Tsai Y, Mezian K, Ricci V, et al.
Diagnostics (Basel)
. 2023 Jun;
13(11).
PMID: 37296780
Ultrasound has emerged as a highly valuable tool in imaging peripheral nerve lesions in the wrist region, particularly for common pathologies such as carpal tunnel and Guyon's canal syndromes. Extensive...